10 stories mentioning HKG:3933Updated just now
Every FINWIRES story that references HKG:3933, newest first.
United Laboratories International (HKG:3933) unit The United Bio-Technology (Hengqin)'s investigational new drug applications for UBT48128 tablets were approved by the U.S. Food and Drug Administration (FDA).The approvals are for the indications of overweight or obesity and type 2 diabetes, according to a Tuesday Hong Kong bourse filing by the pharma company.
United Laboratories International (HKG:3933) said its subsidiary United Biotechnology received a $13.5 million milestone payment from Novo Nordisk related to the global Phase II clinical trial of UBT251 Injection for overweight or obesity treatment, according to a Thursday Hong Kong bourse filing.Shares of the pharmaceutical company were up over 2% in recent trade.The payment was received under an exclusive license agreement for UBT251. The company is eligible for up to $1.8 billion in development and sales milestone payments, along with tiered royalties tied to annual net sales.
United Laboratories International (HKG:3933) said China's National Medical Products Administration approved a new specification of its sodium hyaluronate eye drops, according to a Tuesday filing with the Hong Kong bourse.The approval covers a 0.3% multi-dose formulation for treating corneal and conjunctival epithelial damage associated with dry eye syndrome and other eye conditions.Shares of the bulk medicine company were up over 1% in afternoon trade on Wednesday.
United Laboratories International (HKG:3933) unit Zhuhai United Laboratories Zhongshan Branch obtained approval in China for certain marketing applications for its Tadalafil tablets.The National Medical Products Administration granted three applications for the drug for erectile dysfunction and ED associated with benign prostatic hyperplasia, according to a Thursday filing.
United Laboratories International (HKG:3933) wholly owned subsidiary, Zhuhai United Laboratories, received approval from China's National Medical Products Administration to begin clinical trials of TUL321 capsules, according to a Thursday Hong Kong bourse filing.TUL321 is a next-generation complement factor B inhibitor being developed for autoimmune and complement-mediated diseases, the filing said.
The United Laboratories International (HKG:3933) plans to repurchase up to HK$200 million of its shares on the open market under a shareholder-approved mandate, according to a Thursday Hong Kong bourse filing.The company said the buyback will be funded by internal cash resources, and shares repurchased under the plan will be canceled.
The United Laboratories International (HKG:3933) unit Zhuhai United Laboratories obtained approval for the clinical trial of TUL108 for Injection from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug is intended to treat infections caused by Gram-negative or Gram-positive bacteria, including complicated urinary tract infections, complicated intra-abdominal infections, pulmonary infections, and bloodstream infections.
The United Laboratories International (HKG:3933) said Thursday a subsidiary's clinical trial application for its long-acting weekly insulin product secured approval in China.Specifically, China's National Medical Products Administration cleared the testing for United Bio-Technology (Hengqing)'s UBT38006 injection.
The United Laboratories International (HKG:3933) unit Zhuhai United Laboratories obtained approval for the new drug application of its TUL321 Capsules from the US Food and Drug Administration (FDA), according to a Tuesday Hong Kong bourse filing.The FDA also accepted an application for the clinical trial registration of the drug.The drug is intended to be used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy, age-related macular degeneration, multiple sclerosis, and myasthenia gravis.
The United Laboratories International (HKG:3933) unit Zhuhai United Bio-Pharmaceutical obtained approval for a clinical trial of dupilumab bio-similar from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The approved indication is for atopic dermatitis.
